ÂÜÀòÂÒÂ×

Hui Xin Ong serves as the Chief Scientific Officer at Ab Initio Pharma since 2019, overseeing formulation R&D and manufacturing in compliance with pharmaceutical regulations. Concurrently, Hui Xin holds positions as a Senior Research Fellow at Macquarie University and Research Leader at Woolcock Institute of Medical Research from July 2021. Previously, Hui Xin was a Lecturer at the University of Sydney, where responsibilities included directing the award-winning Master of Medicine Program. Hui Xin's postdoctoral experience includes roles at the Woolcock Institute and University of Southampton, focusing on respiratory drug delivery and clinical pharmacokinetics. Education includes a PhD in Pharmaceutical Sciences and a Bachelor of Pharmacy with first-class honors, both from the University of Sydney.